Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12631618rdf:typepubmed:Citationlld:pubmed
pubmed-article:12631618lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:12631618lifeskim:mentionsumls-concept:C0007134lld:lifeskim
pubmed-article:12631618lifeskim:mentionsumls-concept:C0023828lld:lifeskim
pubmed-article:12631618lifeskim:mentionsumls-concept:C0017337lld:lifeskim
pubmed-article:12631618lifeskim:mentionsumls-concept:C0441655lld:lifeskim
pubmed-article:12631618lifeskim:mentionsumls-concept:C0332256lld:lifeskim
pubmed-article:12631618lifeskim:mentionsumls-concept:C0750502lld:lifeskim
pubmed-article:12631618pubmed:issue3lld:pubmed
pubmed-article:12631618pubmed:dateCreated2003-3-12lld:pubmed
pubmed-article:12631618pubmed:abstractTextImmunotherapy is the most effective treatment against metastatic renal cell carcinoma (RCC). However, the response rate is approximately 15%. More effective therapy is, therefore, needed for patients with metastatic RCC. We then examined the antitumor effect of cationic multilamellar liposome containing human IFN-beta (huIFN-beta) gene (IAB-1) against RCC.lld:pubmed
pubmed-article:12631618pubmed:languageenglld:pubmed
pubmed-article:12631618pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12631618pubmed:citationSubsetIMlld:pubmed
pubmed-article:12631618pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12631618pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12631618pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12631618pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12631618pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12631618pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12631618pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12631618pubmed:statusMEDLINElld:pubmed
pubmed-article:12631618pubmed:monthMarlld:pubmed
pubmed-article:12631618pubmed:issn1078-0432lld:pubmed
pubmed-article:12631618pubmed:authorpubmed-author:HatanoManabuMlld:pubmed
pubmed-article:12631618pubmed:authorpubmed-author:YoshidaJunJlld:pubmed
pubmed-article:12631618pubmed:authorpubmed-author:NakanishiHiro...lld:pubmed
pubmed-article:12631618pubmed:authorpubmed-author:MizutaniYoich...lld:pubmed
pubmed-article:12631618pubmed:authorpubmed-author:KawauchiAkihi...lld:pubmed
pubmed-article:12631618pubmed:authorpubmed-author:MikiTsuneharu...lld:pubmed
pubmed-article:12631618pubmed:authorpubmed-author:UkimuraOsamuOlld:pubmed
pubmed-article:12631618pubmed:authorpubmed-author:MizunoMasaaki...lld:pubmed
pubmed-article:12631618pubmed:authorpubmed-author:ShiraishiTaku...lld:pubmed
pubmed-article:12631618pubmed:issnTypePrintlld:pubmed
pubmed-article:12631618pubmed:volume9lld:pubmed
pubmed-article:12631618pubmed:ownerNLMlld:pubmed
pubmed-article:12631618pubmed:authorsCompleteYlld:pubmed
pubmed-article:12631618pubmed:pagination1129-35lld:pubmed
pubmed-article:12631618pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:12631618pubmed:meshHeadingpubmed-meshheading:12631618...lld:pubmed
pubmed-article:12631618pubmed:meshHeadingpubmed-meshheading:12631618...lld:pubmed
pubmed-article:12631618pubmed:meshHeadingpubmed-meshheading:12631618...lld:pubmed
pubmed-article:12631618pubmed:meshHeadingpubmed-meshheading:12631618...lld:pubmed
pubmed-article:12631618pubmed:meshHeadingpubmed-meshheading:12631618...lld:pubmed
pubmed-article:12631618pubmed:meshHeadingpubmed-meshheading:12631618...lld:pubmed
pubmed-article:12631618pubmed:meshHeadingpubmed-meshheading:12631618...lld:pubmed
pubmed-article:12631618pubmed:meshHeadingpubmed-meshheading:12631618...lld:pubmed
pubmed-article:12631618pubmed:meshHeadingpubmed-meshheading:12631618...lld:pubmed
pubmed-article:12631618pubmed:meshHeadingpubmed-meshheading:12631618...lld:pubmed
pubmed-article:12631618pubmed:meshHeadingpubmed-meshheading:12631618...lld:pubmed
pubmed-article:12631618pubmed:meshHeadingpubmed-meshheading:12631618...lld:pubmed
pubmed-article:12631618pubmed:meshHeadingpubmed-meshheading:12631618...lld:pubmed
pubmed-article:12631618pubmed:meshHeadingpubmed-meshheading:12631618...lld:pubmed
pubmed-article:12631618pubmed:meshHeadingpubmed-meshheading:12631618...lld:pubmed
pubmed-article:12631618pubmed:meshHeadingpubmed-meshheading:12631618...lld:pubmed
pubmed-article:12631618pubmed:meshHeadingpubmed-meshheading:12631618...lld:pubmed
pubmed-article:12631618pubmed:meshHeadingpubmed-meshheading:12631618...lld:pubmed
pubmed-article:12631618pubmed:meshHeadingpubmed-meshheading:12631618...lld:pubmed
pubmed-article:12631618pubmed:meshHeadingpubmed-meshheading:12631618...lld:pubmed
pubmed-article:12631618pubmed:meshHeadingpubmed-meshheading:12631618...lld:pubmed
pubmed-article:12631618pubmed:meshHeadingpubmed-meshheading:12631618...lld:pubmed
pubmed-article:12631618pubmed:meshHeadingpubmed-meshheading:12631618...lld:pubmed
pubmed-article:12631618pubmed:year2003lld:pubmed
pubmed-article:12631618pubmed:articleTitleSignificant antitumoral activity of cationic multilamellar liposomes containing human IFN-beta gene against human renal cell carcinoma.lld:pubmed
pubmed-article:12631618pubmed:affiliationDepartment of Urology, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan.lld:pubmed
pubmed-article:12631618pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:12631618pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12631618lld:pubmed